Board of Directors
Noubar Afeyan, PhD Founder and Executive Chairman Noubar Afeyan is Managing Partner and CEO of Flagship Ventures. He is a recognized technologist and entrepreneur, having founded and helped build several successful life science and technology startups during the past 17 years. A Senior Lecturer at MIT in both the Sloan School of Management and the Biological Engineering Division, Noubar has authored numerous scientific publications and patents. He earned his Ph.D. in Biochemical Engineering from MIT. Prior to co-founding Flagship Ventures, an early stage venture firm in 1999, Noubar participated in launching six highly successful new ventures. He was the Founder, Chairman, and CEO of PerSeptive Biosystems (formerly Nasdaq: PBIO), a leader in the bio-instrumentation field. He also served as Chairman of the Board of ChemGenics Pharmaceuticals, a privately held spin-off company of PerSeptive. After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of their tracking stock subsidiary, Celera Genomics (NYSE: CRA). He has also been a founding team member, investor and active board member/advisor of Antigenics (Nasdaq: AGEN), Color Kinetics (Nasdaq: CLRK) and EXACT Sciences (Nasdaq: EXAS). Noubar currently serves as a Director for several Flagship portfolio companies. Harrison M. Bains Director Mr. Bains joined our board of directors in June 2007. Mr. Bains served as Vice President and Treasurer of Bristol Myers Squibb Company from 1988 until his retirement in 2004. Mr. Bains' career also includes serving as Senior Vice President of the Primary Industries Group at Chase Manhattan Bank in 1987 and 1988 and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. Mr. Bains earned an M.B.A. from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School. Mr. Bains serves on the board of directors and is the chair of the audit committee of MGI Funds, Inc. He is a member of the boards of trustees of the University of Redlands, the Overlook Hospital Foundation and the Greater Newark Conservancy. back to topJoseph Davie, MD, PhD Dr. Davie joins BG Medicine after holding positions as Senior Vice President, Department of Research at Biogen, Inc. and Corporate Senior Vice President, Science and Technology, at G.D. Searle & Co. Before entering the corporate world, Dr. Davie was Head of the Department of Microbiology and Immunology at Washington University School of Medicine, St. Louis, Missouri. Dr. Davie received his PhD in bacteriology from Indiana University and his MD from Washington University School of Medicine. back to topTimothy Harris, PhD Dr. Harris joined BG Medicine as a member of our Board of Directors in April 2007. Dr. Harris has served as the Director of the Advanced Technology Program at SAIC Frederick since January 2007. Prior to holding this position, he served as the President & Chief Executive Officer of Novasite Pharmaceuticals from March 2005 to September 2006. Prior to this, he served as Chief Executive Officer for Structural GenomiX (now SGX Pharma), a drug discovery and development company focused on innovative cancer therapeutics from June 2003 to December 2004 and as its President and Chief Executive Officer from April 1999 to June 2003. Dr. Harris received his Ph.D. in Molecular Virology, University of Birmingham, UK. Pieter Muntendam, MD President Pieter Muntendam, MD, is a biopharmaceutical and healthcare executive with 20 years of business experience ranging from multinational corporations to early stage enterprises. He received his MD from Leiden University in The Netherlands, where he began his career with Organon International and went on to hold key roles in some of the world's largest pharmaceutical firms. As Vice President of Care Management at Glaxo Wellcome (now GlaxoSmithKline), Dr. Muntendam was responsible for the development and implementation of its entry strategy within the field of care and disease management. Previously he was Vice President of Research and Development, International, and a member of the Board of Directors for two Johnson & Johnson operating companies. Most recently he led the BioPharmaceutical and Healthcare practice at NetNumina, a professional services company focused on leveraging information technology to improve biopharma yield and efficiency. Dr. Muntendam's extensive experience with early stage companies includes founding health management firm ProMedex, acquired by SHPS in 2004; and co-founding a subsidiary of Millennium Pharmaceuticals, Vitivity, where he served as Vice President of Medicine. Stelios Papadopoulos, PhD Fondation Sante, Chairman Dr. Stelios Papadopoulos’ career in biotech and pharma spans more than two decades. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette. Pieter van der Meer, MSc General Partner with Gilde Healthcare Partners (The Netherlands) Mr. van der Meer is General Partner in the Biotechnology and Nutrition Fund at Gilde, where has has a focus on biotechnology start-up and early stage investments in companies with novel technologies, platforms and drug discovery approaches. Mr. van der Meer joined Gilde in 1998 after several years working with KPMG Management Consulting where he led due diligence projects in the pharmaceutical sector. Mr. van der Meer earned his MSc in Chemistry at Leiden University where he specialized in bio-organic synthesis and molecular modeling and also holds a Degree in Commercial Economics. Daniel Wang, PhD Institute Professor of Chemical Engineering, MIT Dr. Wang's joins BG Medicine's board as an expert and world leader in protein research. Dr. Wang's current work as Institute Professor of Chemical Engineering includes research into the production of recombinant proteins, glycoprotein quality and protein stabilization. He has numerous publications and awards, including the Amgen Biochemical Engineering Award, 1995. Dr. Wang earned his PhD at the University of Pennsylvania, and his SM and SB degree at MIT.
|